News $40bn Teva generic deal awaits antitrust approval Acquisition of Allergan's generics business ready.
Articles Teva: looking for innovation and growth in ‘space between’ b... Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
